Table 2.
Patient Characteristics at Diagnosis Separated by Cachexia Status or Tumor SUVMax Cut-point of 8.5. IQR, interquartile range
| Cachexia | SUVMax | |||
|---|---|---|---|---|
| No cachexia (%)a | Cachexia (%)a | < 8.5 (%)a | ≥ 8.5 (%)a | |
| Number of patients | 58 | 68 | 54 | 72 |
| Median age | 66, IQR: 59–74 | 59, IQR: 54–69 | 62.5, IQR: 55–69.5 | 63, IQR: 54.8–71 |
| Female | 12 (20.7%) | 14 (20.6%) | 13 (24.1%) | 13 (18.1%) |
| Race: | ||||
| Asian | 2 (3.5%) | 4 (5.9%) | 3 (5.6%) | 3 (4.2%) |
| Black | 4 (6.9%) | 13 (19.1%)b | 5 (9.3%) | 12 (16.7%) |
| Caucasian | 50 (86.2%)b | 41 (60.3%) | 40 (74.1%%) | 51 (70.8%) |
| Hispanic | 2 (3.5%) | 10 (14.7%)b | 6 (11.1%) | 6 (8.3%) |
| Tumor Site | ||||
| Esophagus | 39 (67.2%) | 48 (70.6%) | 30 (55.6%) | 57 (79.2%) |
| Cardia | 19 (32.8%) | 20 (29.4%) | 24 (44.4%) | 15 (20.8%) |
| Diabetes | 15 (25.9%) | 10 (14.7%) | 15 (27.8%) | 10 (13.9%) |
| Tobacco | 44 (75.9%) | 48 (71.6%) | 35 (66.0%) | 57 (79.2%) |
| Alcohol | 34 (61.8%) | 36 (53.7%) | 28 (56.0%) | 42 (58.3%) |
| Histology: | ||||
| Adenocarcinoma | 38 (65.5%) | 41 (60.3%) | 38 (70.4%) | 41 (56.9%) |
| Squamous carcinoma | 15 (25.9%) | 22 (32.4%) | 12 (22.2%) | 25 (34.7%) |
| Signet ring carcinoma | 2 (3.5%) | 4 (5.9%) | 3 (5.6%) | 3 (4.2%) |
| Other | 3 (5.2%) | 1 (1.5%) | 1 (1.9%) | 3 (4.2%) |
| Tumor Grade: | ||||
| 1 | 3 (6.0%) | 4 (6.6%) | 1 (2.1%) | 6 (9.5%) |
| 2 | 20 (40.0%) | 25 (41.0%) | 16 (33.3%) | 29 (46.0%) |
| 3 | 27 (54.0%) | 32 (52.5%) | 31 (64.6%)b | 28 (44.4%) |
| Tumor Stage: | ||||
| 1 | 5 (9.1%) | 1 (4.7%) | 7 (13.7%)b | 1 (1.5%) |
| 2 | 17 (30.9%) | 12 (18.8%) | 15 (29.4%) | 14 (20.6%) |
| 3 | 26 (47.3%) | 34 (53.1%) | 25 (49.0%) | 35 (51.5%) |
| 4 | 7 (12.7%) | 15 (23.4%) | 4 (7.8%) | 18 (26.5%)b |
a
% derived from division by characteristic column total available, ex: (female with no cachexia ÷ total no cachexia)×100 = 20.7% or (12÷58)×100 = 20.7%
b
Significantly higher incidence of row category (P<.05) within population characteristic group